RIPK1 and cancer: Recent studies have shown that genetic knockout (KO) of RIPK1 in cancer cells significantly sensitizes tumors to anti-PD1, leading to drastic changes in the tumor microenvironment (TME), including increased infiltration of effector T cells, reduction of immunosuppressive myeloid cells, and enhanced immunostimulatory cytokine secretion5–7.